BNBalázs Tamás Németh

Balázs Tamás Németh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Balázs Tamás Németh has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of speckle-tracking echocardiography with invasive hemodynamics for the detection of characteristic cardiac dysfunction in type-1 and type-2 diabetic rat models

    by Csaba Mátyás, Attila Kovács, Balázs Tamás Németh, Attila Oláh, Szilveszter Braun, Márton Tokodi, Bálint András Barta, Kálmán Benke, Mihály Ruppert, Bálint Károly Lakatos, et al.

    Measurement of systolic and diastolic function in animal models is challenging by conventional non-invasive methods. Therefore, we aimed at comparing speckle-tracking echocardiography (STE)-derived parameters to the indices of left ventricular (LV) pressure–volume (PV) analysis to detect cardiac dysfunction in rat models of type-1 (T1DM) and type-2 (T2DM) diabetes mellitus. Rat models of T1DM (induced by 60 mg/kg streptozotocin, n = 8) and T2DM (32-week-old Zucker Diabetic Fatty rats, n = 7) and corresponding control animals (n = 5 and n = 8, respectively) were compared. Echocardiography and LV PV analysis were performed. LV short-axis recordings were used for STE analysis. Global circumferential strain, peak strain rate values in systole (SrS), isovolumic relaxation (SrIVR) and early diastole (SrE) were measured. LV contractility, active relaxation and stiffness were measured by PV analysis. In T1DM, contractility and active relaxation were deteriorated to a greater extent compared to T2DM. In contrast, diastolic stiffness was impaired in T2DM. Correspondingly, STE described more severe systolic dysfunction in T1DM. Among diastolic STE parameters, SrIVR was more decreased in T1DM, however, SrE was more reduced in T2DM. In T1DM, SrS correlated with contractility, SrIVR with active relaxation, while in T2DM SrE was related to cardiac stiffness, cardiomyocyte diameter and fibrosis. Strain and strain rate parameters can be valuable and feasible measures to describe the dynamic changes in contractility, active relaxation and LV stiffness in animal models of T1DM and T2DM. STE corresponds to PV analysis and also correlates with markers of histological myocardial remodeling.


  • A hipertrófiás myocardium reverz elektromos remodellációjának vizsgálata patkánymodellben

    by Mihály Ruppert, Bálint András Barta, Sevil Korkmaz-Icöz, Shiliang Li, Attila Oláh, Csaba Mátyás, Balázs Tamás Németh, Kálmán Benke, Alex Ali Sayour, Matthias Karck, et al.

  • A hasonló fokú fiziológiás és patológiás balkamra-hipertrófia különböző in vivo hemodinamikai következményekhez vezet

    by Attila Oláh, Alex Ali Sayour, Balázs Tamás Németh, Csaba Mátyás, László Hidi, Árpád Lux, Mihály Ruppert, Dalma Kellermayer, Lilla Szabó, Marianna Török, et al.

  • Open Access

    The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus

    by Csaba Mátyás, Balázs Tamás Németh, Attila Oláh, László Hidi, Ede Birtalan, Dalma Kellermayer, Mihály Ruppert, Sevil Korkmaz-Icöz, Gábor Kökény, Eszter Mária Horváth, et al.

    Diabetes mellitus (DM) leads to the development of diabetic cardiomyopathy, which is associated with altered nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) signalling. Cardioprotective effects of elevated intracellular cGMP-levels have been described in different heart diseases. In the current study we aimed at investigating the effects of pharmacological activation of sGC in diabetic cardiomyopathy. Type-1 DM was induced in rats by streptozotocin. Animals were treated either with the sGC activator cinaciguat (10 mg/kg/day) or with placebo orally for 8 weeks. Left ventricular (LV) pressure–volume (P–V) analysis was used to assess cardiac performance. Additionally, gene expression (qRT-PCR) and protein expression analysis (western blot) were performed. Cardiac structure, markers of fibrotic remodelling and DNA damage were examined by histology, immunohistochemistry and TUNEL assay, respectively. DM was associated with deteriorated cGMP signalling in the myocardium (elevated phosphodiesterase-5 expression, lower cGMP-level and impaired PKG activity). Cardiomyocyte hypertrophy, fibrotic remodelling and DNA fragmentation were present in DM that was associated with impaired LV contractility (preload recruitable stroke work (PRSW): 49.5 ± 3.3 vs. 83.0 ± 5.5 mmHg, P < 0.05) and diastolic function (time constant of LV pressure decay (Tau): 17.3 ± 0.8 vs. 10.3 ± 0.3 ms, P < 0.05). Cinaciguat treatment effectively prevented DM related molecular, histological alterations and significantly improved systolic (PRSW: 66.8 ± 3.6 mmHg) and diastolic (Tau: 14.9 ± 0.6 ms) function. Cinaciguat prevented structural, molecular alterations and improved cardiac performance of the diabetic heart. Pharmacological activation of sGC might represent a new therapy approach for diabetic cardiomyopathy.


  • Pharmacological activation of the souble guanylate cyclase inhibits pressure overload-induced cardiac hypertrophy

    by Balazs Tamas Nemeth, Csaba Matyas, Attila Olah, Laszlo Hidi, Mihaly Ruppert, Arpad Lux, Dalma Kellermayer, Gergo Merkely, Bela Merkely, Tamas Radovits